Vol 16, No 4 (2023)
Guidelines / Expert consensus
Published online: 2023-10-18
Recommendations for the prevention of Herpes zoster in solid organ transplant recipients in Poland
DOI: 10.5603/rdatf.97835
Renal Disease and Transplantation Forum 2023;16(4):120-126.
Abstract
Herpes zoster (i.e. shingles) is a widespread and common infectious disease caused by reactivation of the varicella zoster virus. Although the cutaneous manifestation of the disease is the most common, shingles is also associated with numerous complications, such as neurological, including postherpetic neuralgia. It is estimated that one-third of general population will develop herpes zoster during their lifetime and the incidence in the solid organ recipients group is even higher. What is more the transplant recipients are more likely to suffer from severe complications of the disease. The most effective method of preventing herpes zoster is vaccination. The only available in Poland and recommended vaccine is the recombinant, adjuvanted zoster vaccine. Its safety and effectiveness was proven in both general, adult population and solid organ recipients.
In this article, we present the position of experts in transplantation and infectious diseases on herpes zoster prevention in solid organ transplant recipients population. The group includes kidney, liver, lung and heart recipients.
Keywords: herpes zoster preventionsolid organ transplant recipientsvaccination
References
- Weller TH. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med. 1983; 309(23): 1434–1440.
- Zerboni L, Sen N, Oliver SL, et al. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol. 2014; 12(3): 197–210.
- Tseng HFu, Bruxvoort K, Ackerson B, et al. The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence. J Infect Dis. 2020; 222(5): 798–806.
- Schmader K. Herpes Zoster. Clin Geriatr Med. 2016; 32(3): 539–553.
- John AR, Canaday DH. Herpes Zoster in the Older Adult. Infect Dis Clin North Am. 2017; 31(4): 811–826.
- Marra F, Parhar K, Huang B, et al. Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis. 2020; 7(1): ofaa005.
- Bhavsar A, Lonnet G, Wang C, et al. Increased Risk of Herpes Zoster in Adults ≥50 Years Old Diagnosed With COVID-19 in the United States. Open Forum Infect Dis. 2022; 9(5): ofac118.
- Yenikomshian MA, Guignard AP, Haguinet F, et al. The epidemiology of herpes zoster and its complications in Medicare cancer patients. BMC Infect Dis. 2015; 15: 106.
- Varicella and herpes zoster vaccines: WHO position paper, June 2014--Recommendations. Vaccine. 2016; 34(2): 198–199.
- Johnson RW, Alvarez-Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015; 3(4): 109–120.
- Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses. 2022; 14(2).
- Curran D, Matthews S, Boutry C, et al. Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical Trials. Infect Dis Ther. 2022; 11(6): 2265–2277.
- Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002; 66(9): 1723–1730.
- Bienkowski C, Kowalczyk M, Talarek E, et al. Meningitis and Ramsay-Hunt syndrome in a 17-year old girl. Neuroendocrinol Lett. 2019; 40: 149–151.
- Albrecht P, Patrzałek M, Goryński P. Zagrożenie półpaścem i jego powikłaniami w Polsce i na świecie w zależności od wieku. Przegl Epidemiol. 2015; 69: 841–843.
- Dworkin RH, Gnann JW, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008; 9(1 Suppl 1): S37–S44.
- Jung BF, Johnson RW, Griffin DRJ, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004; 62(9): 1545–1551.
- Gross GE, Eisert L, Doerr HW, et al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. J Dtsch Dermatol Ges. 2020; 18(1): 55–78.
- Parameswaran GI, Drye AF, Wattengel BA, et al. Increased Myocardial Infarction Risk Following Herpes Zoster Infection. Open Forum Infect Dis. 2023; 10(4): ofad137.
- Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014; 348: g2911.
- Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med. 2005; 352(22): 2266–2267.
- Pergam SA, Forsberg CW, Boeckh MJ, et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011; 13(1): 15–23.
- Kho MML, Roest S, Bovée DM, et al. Herpes Zoster in Solid Organ Transplantation: Incidence and Risk Factors. Front Immunol. 2021; 12: 645718.
- Kim W, Kim S, Oh J, et al. Incidence and risk factors for herpes zoster after adult liver transplantation. Ann Surg Treat Res. 2019; 96(2): 95–99.
- Sullivan KM, Farraye FA, Winthrop KL, et al. Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions. Vaccine. 2023; 41(1): 36–48.
- Davis AR, Sheppard J. Herpes Zoster Ophthalmicus Review and Prevention. Eye Contact Lens. 2019; 45(5): 286–291.
- Gabutti G, Valente N, Sulcaj N, et al. Italian Universities and Epidemiology. [Herpes Zoster and its prevention in Italy. Scientific consensus statement]. Ig Sanita Pubbl. 2014; 70(1): 111–127.
- Lal H, Cunningham AL, Godeaux O, et al. ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015; 372(22): 2087–2096.
- Cunningham AL, Heineman TC, Lal H, et al. ZOE-50/70 Study Group, ZOE-50/70 Study Group, ZOE-70 Study Group, ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015; 372(22): 2087–2096.
- Kim JH, Johnson R, Kovac M, et al. Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials. Pain. 2023; 164(4): 741–748.
- Chlibek R, Pauksens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016; 34(6): 863–868.
- Duchini A, Goss JA, Karpen S, et al. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev. 2003; 16(3): 357–364.
- Kumar D. Immunizations following solid-organ transplantation. Curr Opin Infect Dis. 2014; 27(4): 329–335.
- Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Z-041 Study Group. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. Clin Infect Dis. 2020; 70(2): 181–190.
- Bastidas A, de la Serna J, El Idrissi M, et al. ZOE-HSCT Study Group Collaborators. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2019; 322(2): 123–133.
- Dagnew AF, Ilhan O, Lee WS, et al. Zoster-039 study group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019; 19(9): 988–1000.
- Pergam SA, Limaye AP. AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33(9): e13622.
- Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(3): 80–84.
- Strezova A, Diez-Domingo J, Al Shawafi K, et al. Zoster-049 Study Group. Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination. Open Forum Infect Dis. 2022; 9(10): ofac485.
- Lindemann M, Baumann C, Wilde B, et al. Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients. Vaccines (Basel). 2022; 10(6).
- Roch T, Wehler P, Blazquez-Navarro A, et al. Kidney Transplant Patients Generate Varicella Zoster-Reactive T-cell and Humoral Immunity Following Protein-based Varicella Zoster Vaccination. Transplantation. 2023; 107(2): e58–e59.
- L'Huillier AG, Hirzel C, Ferreira VH, et al. Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients. Transplantation. 2021; 105(10): 2316–2323.
- Levitsky J, Kalil A, Meza JL, et al. Herpes zoster infection after liver transplantation: a case-control study. Liver Transpl. 2005; 11(3): 320–325.
- Alukal JJ, Naqvi HA, Thuluvath PJ. Vaccination in Chronic Liver Disease: An Update. J Clin Exp Hepatol. 2022; 12(3): 937–947.
- Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018; 67(3): 103–108.
- Hirzel C, L'Huillier AG, Ferreira VH, et al. Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients. Am J Transplant. 2021; 21(6): 2246–2253.
- Barghash MH, Taimur S, Rana M, et al. Recombinant herpes zoster vaccine after heart transplantation: A single-center experience. J Heart Lung Transplant. 2020; 39(12): 1501–1503.
- Kittleson M, Patel J, Chang D, et al. Effect of the Shingles Vaccine in Altering Clinical Shingles after Heart Transplantation. The Journal of Heart and Lung Transplantation. 2020; 39(4): S479.
